Travel grants from Novo Nordisk for ScanBalt scientists attending the 8th World Congress on Inflammation in Copenhagen – deadline 15 January
Novo Nordisk offers travel grant for ScanBalt actors to World Congress on Inflammation
Attendants who wish to compete for the grants must make sure to submit their abstract for evaluation before the official deadline, January 15, 2007.
Travel support to World Congress on Inflammation 2007 by Novo Nordisk
The World Congress on Inflammation (WCI) is organized by the International Association of Inflammation Societies (www.inflammation2007.dk). The first WCI was in 1993 in Vienna, and has subsequently been held every second year. The 8th WCI will be held in Copenhagen, Denmark, June 16-20, 2007.
The event is expected to attract 1000+ experts and scientists in the field of immunology and inflammation from all over the world and representing all sectors (academia, clinical centres and industry). Please visit the above website for the preliminary program.
Novo Nordisk is the biggest pharmaceutical company headquartered in Scandinavia (www.novonordisk.com). Its main facilities are located in Denmark but Novo Nordisk has facilities all over the world including a R&D unit in Beijing.
Novo Nordisk offers to help 10 scientists from ScanBalt BioRegion in the field of immunology and/or inflammation to attend the 8th WCI in Copenhagen. The 10 individual travel grants will amount to a maximum of 500 US$ for each application.
The purpose of the Novo Nordisk Travel Grant is to promote scientific co-operation between scientists from ScanBalt BioRegion in the field of immunology and inflammation.
The procedure for application and selection of the travel grants are:
1. Applicants should submit, by e-mail, a letter of motivation (max 1 page), his/her CV, and the abstract of a poster to ICS (International Congress Service) according to the specifications found on the WCI8 website (www.inflammation2007.dk). The application must be clearly marked Novo Nordisk Travel Grant Application. Deadline is December 1, 2006.
2. The Scientific Committee of WCI will select c. 10 qualified candidates. There will be only one recipient for each poster.
The names of the Novo Nordisk Travel Grant recipients will be announced no later than February 5, 2007. The recipients will be asked to present their posters at the WCI and some of them may be selected for oral presentations.
About Novo Nordisk Travel Grants:
Dr. Boerge Diderichsen
Vice President, Professor, Ph.D.
Corporate Research Affairs
Novo Allé 6A1
DK-2880 Bagsvaerd, Denmark
Tel: +45 4442 3401
About 8th WCI:
Dr. Ian Ahnfelt-Roenne,
President of WCI8
Vice President, MSc PhD,
Biopharmaceuticals Research Unit
Novo Nordisk, Novo Nordisk Park, F6.2.59
DK-2760 Måløv, Denmark
Tel: +45 4443 4541
Novo Nordisk A/S is a founding member of ScanBalt